Product range of ALSI Pharma will be expanded by a new antidepressant Venlafaxine

The Ministry of Healthcare of the Russian Federation gave a permission to the ALSI Pharma, CJSC, to manufacture a drug called Venlafaxine (Registration Certificate LP-002202 of August 26, 2013) in a tabloid form.

This innovative for the company medicine does not enter our product range by accident. It extends our line-up of antidepressants, which we have recently supported registering new and advanced molecules that had gone out of patent protection not long ago. These molecules often have a unique chemical structure that does not fit the existing chemical classification for antidepressants (tricyclic, tetracyclic, etc.), for example, Venlafaxine.

At the same time, we keep producing fore medicines, well proven in clinics, such as, for example, amitriptyline tablets or fluoxetine capsules. Thus, we do not only do our best to expand the product range for pharmacies and psychiatrists with drugs already manufactured on a large scale by other domestic enterprises, but also with drugs that come to us mainly from abroad (like the Venlafaxine).

Venlafaxine

The Citalopram is another antidepressant recently registered by the Company. It is a very strong and highly selective serotonin reuptake inhibitor (SSRI). The Venlafaxine is considered less selective as besides the serotonin reuptake (lower in its force as compared with the citalopram) it also inhibits the reuptake of norepinephrine. This causes a softer, balanced and combined effect upon a patient with depression. This also assigns the Venlafaxine to a subgroup of serotonin and norepinephrine reuptake inhibitors (referred to as SNRI or SS&NRI). This recently appeared and still small in number subgroup of antidepressants is very promising for further development and appearance of new molecules.

As a result of the Venlafaxine’s influence, in patient’s nerve synapses, a concentration of released serotonin and norepinephrine credibly increases, which in most cases leads to mood improvement, behaviour normalization, a feeling of relief in physical, mental and emotional spheres, which are usually altered because of depressive disorders. The Venlafaxine medication has low toxicity and an acceptable safety profile. By similar indicators, it is comparable with the subgroup of SSRI.

Please find detail in the Basic Prescribing Information.

The ALSI Pharma will manufacture the Venlafaxine in standard tabloid form of 37.5 mg and 75 mg, with 30 tablets packed in a carton package (3 contour-blister cards with 10 tablets each).

A choice of such doses depends on the original medication produced by the Wyeth (Wyeth Pharmaceuticals) and firstly registered in Russia in 2001 and in many other countries. Now that medication’s name is Effexor distributed by the Pfizer.

These doses most closely correspond to a treatment regimen and medication frequency of administration in the most cases. The medication is only given on prescription in almost all the countries. Before prescribing the drug, please refer to the Basic Prescribing Information for it, where there is the most up to date and detailed information on the Venlafaxine usage.